Patents by Inventor Anusch Peyman

Anusch Peyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody
    Patent number: 10995150
    Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: May 4, 2021
    Assignees: REGENERON PHARMACEUTICALS, INC., SANOFI BIOTECHNOLOGY
    Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
  • METHODS FOR INHIBITING ATHEROSCLEROSIS BY ADMINISTERING AN INHIBITOR OF PCSK9
    Publication number: 20200071422
    Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
    Type: Application
    Filed: July 8, 2019
    Publication date: March 5, 2020
    Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
  • Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
    Patent number: 10494442
    Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: December 3, 2019
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans Ludwig Schäfer, Uwe Schwahn
  • METHODS FOR INHIBITING ATHEROSCLEROSIS BY ADMINISTERING AN INHIBITOR OF PCSK9
    Publication number: 20180244801
    Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, this PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 30, 2018
    Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-ludwig Schaefer, Uwe Schwahn
  • METHODS FOR INHIBITING ATHEROSCLEROSIS BY ADMINISTERING AN INHIBITOR OF PCSK9
    Publication number: 20160115246
    Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.
    Type: Application
    Filed: June 6, 2014
    Publication date: April 28, 2016
    Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-ludwig Schaefer, Uwe Schwahn